Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

STATUS

Recruiting
End date

Jun 28, 2026
participants needed

75
sponsor

GWT-TUD GmbH

Send

Updated on 19 February 2024

See if I qualify

cancer

measurable disease

metastasis

gemcitabine

paclitaxel

antineoplastic

durvalumab

adenocarcinoma

azacitidine

pdac

pancreatic adenocarcinoma

lenalidomide

drug test

antineoplastic agents

romidepsin

ductal adenocarcinoma

pancreatic ductal adenocarcinoma

breast ductal carcinoma

blockade

pancreatic cancer

paclitaxel/gemcitabine

Summary

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients with controlled disease after 3 cycles (Part 1).

Description

The first part of the study will employ a standard 3 + 3 design to test safety and tolerability of histone deacetylase (HDAC) inhibition with Romidepsin (Arm A), DNA methyltransferase (DNMT) inhibition with Azacitidine (Arm B) or both agents (Arm C), in each arm in combination with nab-Paclitaxel/Gemcitabine (Part 1a). Study treatment is given until intolerable toxicity as defined in the protocol. Treatment will escalate until the recommended dose for RDE is identified.

For the expansion part (Part 1b) of the study, one of the treatment arms (Arm C over B over

will be continued using a Simon Two-stage design to a maximum of 35 patients.

All patients from Part 1a and 1b will be treated for a total of three cycles and will then enter the second part of the study in case of disease control with still measurable disease (PR, SD).

In the second part (Part 2) of the study (consolidation therapy), all patients from Part 1 (dose escalation and expansion cohorts from experimental arms and standard arm) who have not progressed after three cycles of nab-Paclitaxel/Gemcitabine with or without additional epigenetic treatment (= at least SD by RECIST 1.1 after 3 cycles) receive sequential immune targeting with PD-L1 blockade (standard fixed dose Durvalumab 1500 mg q4w iv) in combination with low-dose Lenalidomide (10 mg d1-21 q4w po) until documented disease progression.

Details

Condition	Pancreatic Cancer, Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Age	18-100 years
Treatment	Azacitidine, nab-paclitaxel, Gemcitabine, Durvalumab, Romidepsin, Lenalidomide capsule
Clinical Study Identifier	NCT04257448
Sponsor	GWT-TUD GmbH
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients must have histologically confirmed PDAC
	Patients must have metastatic disease (stage IV) and not received prior chemotherapy for stage IV disease
	Patients must not have received the following drugs before: Azacitidine, Romidepsin, any checkpoint-inhibitor or immunomodulating agents such as Immunomodulatory imide drugs (IMiDs)
	Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1
	Male or female, age > 18 years
	Body weight > 30 kg for inclusion into Part 2
	Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
	Patients must have normal organ and marrow function
	Patients must be recovered from the effects of any prior surgery
	Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
	All subjects must agree to refrain from donating blood while on study drug and for 90 days after discontinuation from this study treatment
	All subjects must have a life expectancy of at least 12 weeks
	Females of childbearing potential (FCBP) must agree to utilize two reliable forms of contraception simultaneously without interruption for at least 28 days before starting study drug, while participating in the study, and for at least 90 days after study treatment discontinuation
	Males must agree to use a latex condom during any sexual contact with FCBP or a pregnant female, refrain from donating semen or sperm and not to father a child
Exclusion Criteria
	Patients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events from agents administered more than 4 weeks earlier
	Patients receiving any other investigational agents
	Patients who have previously received Romidepsin, Azacitidine, Lenalidomide or Durvalumab or any programmed cell death-1 (PD1) or programmed cell death ligand 1 (PD-L1) inhibitor or participate currently on another clinical trial
	Patients with untreated or uncontrolled brain metastases or leptomeningeal disease
	Presence of other active illnesses
	Any known cardiac abnormalities such as: congenital long QT syndrome; corrected QT interval (QTc interval) 470 milliseconds. Calculated from 3 ECGs using Fridericia's Correction
	Myocardial infarction within 6 months of cycle 1, day 1 (C1D1)
	Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)
	Symptomatic coronary artery disease (CAD)
	Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or known ejection fraction <40% by multiple gated acquisition scan (MUGA) or <50% by echocardiogram and/or MRI
	A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
	Concomitant use of any drug known to prolong QT interval
	Concomitant use of strong CYP3A4 inhibitors
	Lactating, pregnant or breast feeding
	Patients with any other medical or psychological condition deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
	Diagnosis of immunodeficiency or any condition that requires systemic steroid therapy or other forms of immunosuppressive therapy
	Prior thromboembolic events
	History of other malignancies
	Any uncontrolled active systemic infection
	Major surgery within 4 weeks of first dose of study drug
	Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
	History of stroke or intracranial hemorrhage within 6 months prior to enrollment
	History of interstitial lung disease, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis
	Unable to swallow oral medication or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
	Concomitant use of warfarin or other Vitamin K antagonists
	Known allergy or hypersensitivity to any study drug or any of the study drug excipients
	Unwilling or unable to participate in all required study evaluations and procedures. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information
	Current or prior use of immunosuppressive medication within 14 days before the first dose of Durvalumab
	Active or prior documented autoimmune or inflammatory disorders
	Any unresolved toxicity NCI CTCAE Grade 2 from previous anticancer therapy
	History of allogenic organ transplantation
	Active infection including tuberculosis
	Receipt of live attenuated vaccine within 30 days prior to the first dose of Investigational medicinal product (IMP)
	Subject is an employee of the sponsor

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.